Aikido Pharma
Seite 1 von 2 Neuester Beitrag: 11.09.20 15:16 | ||||
Eröffnet am: | 20.03.20 20:45 | von: Strandläufer | Anzahl Beiträge: | 32 |
Neuester Beitrag: | 11.09.20 15:16 | von: Supertrooper. | Leser gesamt: | 9.439 |
Forum: | Börse | Leser heute: | 0 | |
Bewertet mit: | ||||
Seite: < 1 | 2 > |
Die ehemalige Spherix Inc. heisst nach Durchführung eines Namenswechsels seit 13.03.2020 nunmehr Aikido Pharma Inc. Der äußerst volatile Biotechnologietitel wird unter dem Ticker "AIKI" an der NASDAQ sowie unter der WKN A2P1UN an diversen deutschen Börsen notiert.
https://www.prnewswire.com/news-releases/...pharma-inc-301023121.html
https://www.prnewswire.com/news-releases/...pharma-inc-301023121.html
on COVID-19, Dividend, And Path Forward
https://ih.advfn.com/stock-market/NASDAQ/...r-update-on-covid-19-divi
https://ih.advfn.com/stock-market/NASDAQ/...r-update-on-covid-19-divi
NEW YORK, April 14, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 14,000,000 shares of AIkido's common stock, at a purchase price of $1.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 16, 2020, subject to the satisfaction of customary closing conditions.
NEW YORK, April 15, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), a technology development company committed to the fostering of innovative ideas, announced today the closing of its previously announced registered direct offering with several institutional and accredited investors of 14,000,000 shares of its common stock at a purchase price of $1.00 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled $14.0 million, before deducting placement agent fees and other offering expenses.
NEW YORK, April 20, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the record date for the previously announced distribution to our stockholders of shares of Hoth Therapeutics, Inc. ("Hoth") is April 30, 2020, and the Company is currently working to determine the date of distribution.
NEW YORK, April 21, 2020 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on April 13, 2020, the Company executed a Master License Agreement (the "License Agreement") with the University of Maryland, Baltimore ("UMB"). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.
AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore
https://ir.aikidopharma.com/news-releases/
https://ir.aikidopharma.com/news-releases/